Padma Sathyanarayana

Perioperative Nivolumab in Resectable Lung Cancer

Tina Cascone, Mark M. Awad, Jonathan Spicer et al. · New England Journal of Medicine · 2024 · 356 citations · Full text

Effects of Combined Exenatide and Pioglitazone Therapy on Hepatic Fat Content in Type 2 Diabetes

Padma Sathyanarayana, Medhavi Jogi, Raja Muthupillai et al. · Obesity · 2011 · 123 citations

Pioglitazone Therapy, Fatty Liver Disease, Insulin Signaling +19

Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial

Susan L. Samson, Padma Sathyanarayana, Medhavi Jogi et al. · Diabetologia · 2011 · 106 citations · Full text

Obesity, Metabolic Syndrome, Hepatology +10

LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC

Tina Cascone, Mark M. Awad, J.D. Spicer et al. · Annals of Oncology · 2023 · 100 citations · Full text

Surgical Oncology, Medicine, Pharmacology +8

NF-κB-Inducing Kinase (NIK) Mediates Skeletal Muscle Insulin Resistance: Blockade by Adiponectin

Sanjeev Choudhary, Sandeep Sinha, Yanhua Zhao et al. · Endocrinology · 2011 · 51 citations · Full text

Immunology, Renal Inflammation, Insulin Signaling +19